Injection of optimism as HIV vaccine trial begins
The first doses of an experimental HIV vaccine have been delivered in a phase 1 clinical trial. International AIDS Vaccine Initiative (IAVI), a non-profit scientific...
January 28, 2022
by pharmatimes
Zendal and IAVI Partner for TB Vaccine Candidate
Biofabri and IAVI announced their intention to partner on efficacy trials of tuberculosis (TB) vaccine candidate, MTBVAC.
July 15, 2021
by americanpharmaceuticalreview
Batavia Manufactures IAVI’s Lassa Fever Vax Candidate
Batavia Biosciences has successfully produced vaccine material for a Phase I clinical trial of IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC.
July 15, 2021
by contractpharma
Novel HIV vaccine approach shows promise in “landmark” first-in-human trial
The vaccine was able to target the desired immune cells and could become the first stage of a multi-step vaccine strategy to combat HIV and various other viral diseases.
February 7, 2021
by europeanpharmaceuticalreview
Merck KGaA, IAVI and Serum Institute link up to develop COVID-19 mAbs
German pharma company Merck KGaA has partnered with non-profit scientific research organisation IAVI and Serum Institute of India to develop monoclonal antibodies (mAbs) for COVID-19.
October 26, 2020
by pharmatimes
IAVI, Merck KGaA and Serum Institute partner to develop COVID-19 mAbs
The partnership aims to ensure access to a class of innovative therapies that have, to date, been out of reach in low- and middle-income countries (LMICs).
October 23, 2020
by expresspharma
Merck joins race to develop Covid-19 vaccines and drugs
Merck (MSD) has joined the race to develop vaccines and treatments against Covid-19 with separate agreements with Themis, IAVI and Ridgeback Biotherapeutics.
May 27, 2020
by pharmaceutical-technology
Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever
Batavia Biosciences announces today that the International AIDS Vaccine Initiative (IAVI) and Batavia Biosciences will work together under a grant to advance the development of a Lassa fever vaccine.
December 13, 2018
by b3cnewswire
IAVI Announces Clinical Trial of HIV Vaccine Candidate
The International AIDS Vaccine Initiative (IAVI) announces the start of a Phase I clinical trial (IAVI G001) to test a novel vaccine candidate designed to stimulate the immune system to initiate a first step in the generation of potent proteins, known as
October 12, 2018
by americanpharmaceuticalreview
IAVI Announces Clinical Trial of HIV Vaccine Candidate
The International AIDS Vaccine Initiative (IAVI) announces the start of a Phase I clinical trial (IAVI G001) to test a novel vaccine candidate designed to stimulate the immune system to initiate a first step in the generation of potent proteins...
October 10, 2018
by americanpharmaceuticalreview